Date
2019Journal
Frontiers in ImmunologyPublisher
Frontiers Media S.A.Type
Article
Metadata
Show full item recordAbstract
Clinical observations and accumulating laboratory evidence support a complex interplay between coagulation, inflammation, innate immunity and fibrinolysis in venous thromboembolism (VTE). VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and the subsequent complications of post-thrombotic syndrome (PTS), are significant causes of morbidity and mortality in patients. Clinical risk factors for VTE include cancer, major trauma, surgery, sepsis, inflammatory bowel disease, paralysis, prolonged periods of immobility, and aging. Abnormalities in venous blood flow or stasis initiates the activation of endothelial cells, and in concert with platelets, neutrophils and monocytes, propagates VTE in an intact vein. In addition, inflammatory cells play crucial roles in thrombus recanalization and restoration of blood flow via fibrinolysis and vascular remodeling. Faster resolution of the thrombus is key for improved disease prognosis. While in the clinical setting, anticoagulation therapy is successful in preventing propagation of venous thrombi, current therapies are not designed to inhibit inflammation, which can lead to the development of PTS. Animal models of DVT have provided many insights into the molecular and cellular mechanisms involved in the formation, propagation, and resolution of venous thrombi as well as the roles of key components of the fibrinolytic system in these processes. Here, we review the recent advances in our understanding of fibrinolysis and inflammation in the resolution of VTE. Copyright Copyright 2019 Mukhopadhyay, Johnson, Duru, Buzza, Pawar, Sarkar and Antalis.Keyword
DVTFibrinolysis
Inflammation
Innate immunity
PE
Plasminogen
Venous thromboembolism
Venous thrombus resolution
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068968703&doi=10.3389%2ffimmu.2019.01348&partnerID=40&md5=e1f2b36631d5edcd2a39ecdfb33bc132; http://hdl.handle.net/10713/10635ae974a485f413a2113503eed53cd6c53
10.3389/fimmu.2019.01348
Scopus Count
Collections
Related articles
- Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms.
- Authors: Nicklas JM, Gordon AE, Henke PK
- Issue date: 2020 Mar 18
- Markers of coagulation activation, inflammation and fibrinolysis as predictors of poor outcomes after pediatric venous thromboembolism: A systematic review and meta-analysis.
- Authors: Zia A, Russell J, Sarode R, Veeram SR, Josephs S, Malone K, Zhang S, Journeycake J
- Issue date: 2017 Dec
- Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis.
- Authors: Hsu C, Brahmandam A, Brownson KE, Huynh N, Reynolds J, Lee AI, Fares WH, Ochoa Chaar CI
- Issue date: 2019 Mar
- Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring.
- Authors: Kessinger CW, Kim JW, Henke PK, Thompson B, McCarthy JR, Hara T, Sillesen M, Margey RJ, Libby P, Weissleder R, Lin CP, Jaffer FA
- Issue date: 2015
- Inflammation in venous thromboembolism: Cause or consequence?
- Authors: Saghazadeh A, Hafizi S, Rezaei N
- Issue date: 2015 Sep